The CEO and CMO selling at $9.01—28% below the May 7 offering price of $11.52—suggests insiders see limited near-term upside post-dilution and post-catalyst. Monitor for additional insider selling in the next 30 days; if C-suite continues to sell, it would reinforce a bearish read. The $300M cash raise funds operations into Q2 2027, but the stock's post-offering slide indicates the market is pricing in heavy dilution.
Price Chart
Executive Summary
CEO Fred Aslan and CMO Subhashis Banerjee sold a combined $308K in open-market sales on May 19, 2026, just 11 days after a $300M dilutive offering priced at $11.52/share and 12 days after positive Phase 2a RA data. The sales are small relative to the $228M market cap (0.14%), but the timing—immediately after a large secondary and at a price ($9.01) well below the offering price—raises concern that insiders are reducing exposure post-dilution and post-catalyst. The cluster is amplified by the cross-filing context of a recent capital raise and earnings release.
Key Financial Metrics
Key Facts
- CEO Fred Aslan sold 27,116 shares for $244K on May 19, 2026 at $9.01
- CMO Subhashis Banerjee sold 7,037 shares for $63K on May 19, 2026 at $9.01
- President Diego Miralles received 310,000 shares via non-cash grants on May 18, 2026 ($0 value)
- Total open-market sales: $308K, representing 0.14% of $228M market cap
- Sales occurred 11 days after a $300M dilutive offering at $11.52/share and 12 days after positive Phase 2a RA data
- Stock price has declined from $12.52 (May 7) to $9.01 (May 19), a 28% drop
Financial Impact
Insider sales of $308K (0.14% of market cap) are modest in absolute terms but notable for timing and price level
Risk Factors
- Further insider selling could signal deteriorating confidence in near-term catalysts
- The $300M offering at $11.52 created massive dilution (26M shares, ~50% of pre-offer float), pressuring the stock
- Pre-revenue biotech with cash burn of ~$23.5M/quarter; positive Phase 2a data may not translate to Phase 3 success
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ARTV-1779241868981 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 20d ago | 8-K | $10.14 $8.91 | ▼ −12.13% | ▼ −11.67% | $6.86 (−32.35%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▲ +3.43% | ▲ +2.83% | $6.86 (+36.42%) |
Sep 4, 2026 28d ago | Insider Cluster | $11.19 $10.88 | ▼ −2.77% | ▼ −2.22% | $6.86 (−38.70%) |
Aug 15, 2026 6w ago | Institutional Cluster | $11.74 $11.68 | ▼ −0.51% | ▲ +0.16% | $6.86 (−41.57%) |
Jul 31, 2026 8w ago | Insider Buy | $10.76 $11.07 | ▲ +2.88% | ▲ +1.08% | $6.86 (−36.25%) |
Jul 28, 2026 9w ago | Insider Buy | $10.53 $10.02 | ▼ −4.84% | ▼ −3.30% | $6.86 (−34.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access